Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIR-1111 Phase 1a in Healthy Volunteers
NCT04725877Phase 1Completed
- Sponsor
- Vir Biotechnology
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing VIR-1111 with Placebo (2 arms). Primary endpoints: Number of participants with any treatment-emergent adverse events (AEs), Number of participants with any serious AEs (SAEs) and 5 more. Started Dec 2020; status: completed.
02
Drugs
VIR-1111
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04725877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04725877.